All AbMole products are for research use only, cannot be used for human consumption.
GW791343 trihydrochloride is a non-competitive human P2X (7) receptor inhibitor with pIC50 of about 7.1. GW791343 trihydrochloride exhibits negative allosteric effects at the human P2X (7) receptor but is a positive allosteric modulator of the rat P2X (7) receptor. GW791343 trihydrochloride competitively interacted at the ATP binding site and so were probably negative allosteric modulators of the P2X (7) receptor. GW791343 trihydrochloride increased responses to BzATP at the F95L mutant receptor, although the magnitude of this effect was not as marked as at the rat ECD, rat–human or domain 1 receptor.
| Molecular Weight | 483.81 |
| Formula | C20H24F2N4O.3HCl |
| CAS Number | 309712-55-8 |
| Solubility (25°C) | DMSO |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related P2 Receptor Products |
|---|
| Prasugrel hydrochloride
Prasugrel hydrochloride is a novel inhibitor of platelet activation and aggregation. |
| GW 791343 dihydrochloride
GW 791343 dihydrochloride is a non-competitive inhibitor of human P2X(7) receptor. |
| Prasugrel
Prasugrel is a platelet inhibitor irreversibly binding to P2Y12 receptors. |
| MRS 2578
MRS2578 is a potent P2Y6 receptor antagonist with IC50 of 37 nM, exhibits insignificant activity at P2Y1, P2Y2, P2Y4,and P2Y11 receptors. |
| PPADS Tetrasodium
PPADS tetrasodium salt is a non-selective P2 purinergic antagonist blocking recombinant P2X1, P2X2, P2X3, P2X5 with IC50 of 1-2.6 μM, native P2Y2-like with IC50 of ~ 0.9 mM, and recombinant P2Y4 receptors with IC50 of ~ 15 mM |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
